Market Overview

AspenBio Announces Dismissal of Class Action and Chipman Lawsuits

AspenBio Pharma, Inc. (Nasdaq: APPY), an in vitro diagnostic company, today announced that the United States District Court for Colorado has dismissed and entered judgment without prejudice in both the class action lawsuit (Case No. 11-cv-00165-REB-KMT) against the company and certain of its former or current officers and directors, and the Mark Chipman lawsuit (Case No. 11-cv-00163-REB-KMT) against the company.

"We are very pleased with the court's decisions," stated Steve Lundy, President and CEO of AspenBio. "We continue to execute on our priority of advancing AppyScore™ toward commercialization."

Posted-In: News Legal

 

Most Popular

Related Articles (APPY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free